Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models
Visualitza/Obre
Autor/a
Ainsua-Enrich, Erola
Urrea Gales, Victor
Pradenas, Edwards
Roca, Núria
Ávila-Nieto, Carlos
Rodríguez de la Concepción, María Luisa
Pedreño-Lopez, Núria
Carabelli, Julieta
Trinité, Benjamin
Ballana, Ester
Riveira-Muñoz, Eva
Izquierdo-Useros, Nuria
Clotet, Bonaventura
Blanco, Julià
Guallar, Victor
Carrillo, Jorge
Data de publicació
2024-02-27ISSN
2059-0105
Resum
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe
determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike
glycoprotein (S-29) that had previously shown high efficacy in young animals. Thirteen to 18-month-old
golden Syrian hamsters (GSH) and 22–23-month-old K18-hCAE2 mice were immunised twice with S-29
protein in AddaVaxTM adjuvant. GSH were intranasally inoculated with SARS-CoV-2 either two weeks or
four months after the booster dose, while all K18-hACE2 mice were intranasally inoculated two weeks
after the second immunisation. Body weight and clinical signs were recorded daily post-inoculation.
Lesions and viral load were investigated in different target tissues. Immunisation induced seroconversion
and production of neutralising antibodies; however, animals were only partially protected from weight
loss. We observed a significant reduction in the amount of viral RNA and a faster viral protein clearance in
the tissues of immunized animals. Infectious particles showed a faster decay in vaccinated animals while
tissue lesion development was not altered. In GSH, the shortest interval between immunisation and
inoculation reduced RNA levels in the lungs, while the longest interval was equally effective in reducing
RNAinnasalturbinates; viral nucleoprotein amount decreased in both tissues. Inmice, immunisation was
able to improve the survival of infected animals.Despite the high protection shown in young animals, S-29
efficacy was reduced in the geriatric population.Our research high lights the importance of testing vaccine
efficacy in older animals as part of preclinical vaccine evaluation.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
619 - Veterinària
Pàgines
12
Publicat per
Nature Research
Publicat a
npj Vaccines
Citació
Usai, Carla, Erola Ainsua-Enrich, Víctor Urrea, Edwards Pradenas, Cristina Lorca-Oró, Ferran Tarrés-Freixas, Núria Bosch Roca, et al. 2024. “Immunisation Efficacy of a Stabilised SARS-CoV-2 Spike Glycoprotein in Two Geriatric Animal Models.” Npj Vaccines 9 (1): 48. doi:10.1038/s41541-024-00840-0.
Número de l'acord de la subvenció
ISCIII/Programa Estatal de fomento de la investigación científica y técnica de excelencia/PI17-01518/ES/Desarrollo de una plataforma de vacunas contra el VIH basada en partículas similares a virus (VLP) envueltas y de alta densidad antigénica/
ISCIII/Programa Estatal de fomento de la investigación científica y técnica de excelencia/PI18-01332/ES/Identificación, aislamiento y caracterización de anticuerpos que interfieren con la acción de los anticuerpos neutralizantes en personas infectadas por el virus de la inmunodeficiencia humana/
MICINN/Programa Estatal de I+D+I orientada a los retos de la sociedad/PID2020-117145RB-I00/ES/NUEVAS TERAPIAS ANTIVIRALES E INMUNOMODULADORAS FRENTE AL SARS-COV-2/
EC/H2020/101046118/EU/RBD Dimer recombinant protein vaccine against SARSCoV2/RBDCOV
Programa
Sanitat Animal
Aquest element apareix en la col·lecció o col·leccions següent(s)
- ARTICLES CIENTÍFICS [2576]
Els següents fitxers sobre la llicència estan associats a aquest element:
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by/4.0/